The FDA indicated paxalisib's overall survival data could support standard approval in glioblastoma, as supported by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback